ABSI vs RXRX vs SDGR vs ALIT vs TWST

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Analysts rate Absci Corporation (ABSI) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -41.

0%, compared to -88. 7% for Alight, Inc. (ALIT). Over 10 years, the gap is even starker: TWST returned +306. 1% versus ALIT's -89. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alight, Inc.

(ALIT) is the lower-risk stock at 1. 40β versus Recursion Pharmaceuticals, Inc. 's 2. 99β — meaning RXRX is approximately 114% more volatile than ALIT relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 192% for Alight, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Twist Bioscience Corporation grew EPS 63. 9% year-over-year, compared to -1924. 1% for Alight, Inc.. Over a 3-year CAGR, RXRX leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Twist Bioscience Corporation (TWST) is the more profitable company, earning -20.

6% net margin versus -41. 1% for Absci Corporation — meaning it keeps -20. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALIT leads at 1. 5% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — SDGR leads at 55. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ALIT: 300.

9% to $3. 75.

In this comparison, ALIT (17.

4% yield) pays a dividend. ABSI, RXRX, SDGR, TWST do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alight, Inc.

(ALIT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (17. 4% yield). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALIT: -89. 1%, RXRX: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ABSI (Healthcare) and RXRX (Healthcare) and SDGR (Healthcare) and ALIT (Technology) and TWST (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ABSI is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; SDGR is a small-cap high-growth stock; ALIT is a small-cap income-oriented stock; TWST is a small-cap high-growth stock. ALIT pays a dividend while ABSI, RXRX, SDGR, TWST do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.